Haemonetics competitors, on the record

Who Haemonetics names

In its own words

1. Abbott Laboratories, Cordis, Teleflex

   Word for word“Our main competitors in vascular access closure include Terumo BCT, Abbott Laboratories, Cordis, and Teleflex, where we compete primarily based on clinical and economic value, ease of use, workflow improvements and patient satisfaction.” 10-K for 2026

2. Boston Scientific, Philips

   Word for word“Competitors such as Abbott Laboratories, Boston Scientific, and Philips pose challenges and opportunities in the coronary physiology segment, each offering their own technologies and solutions.” 10-K for 2026

3. Diagnostica Stago SAS, Sysmex, Werfen

   Word for word“Competition includes routine coagulation tests, such as prothrombin time, partial thromboplastin time and platelet count marketed by various manufacturers, such as Werfen, Diagnostica Stago SAS and Sysmex.” 10-K for 2026

4. Fresenius SE & Co. KGaA, Terumo Blood and Cell Technologies (“Terumo BCT”)

   Word for word“Terumo Blood and Cell Technologies (“Terumo BCT”), Fresenius SE & Co. KGaA, and Abbott Laboratories, in particular, have significant financial and other resources and are strong competitors in a number of our businesses.” 10-K for 2026

5. Nigale, Scinomed

   Word for word“Outside of the U.S., we also compete with Nigale, a Chinese manufacturer that has expanded beyond China into European and South American markets, and Scinomed, a European company with Chinese manufacturing that competes in select European countries as well.” 10-K for 2026

Who names Haemonetics

Companies whose own annual reports name Haemonetics as a competitor.

1. LivaNova names it as “Haemonetics Corporation” · 2025

   Word for word“LivaNova’s primary medical device competitors in the Cardiopulmonary and Neuromodulation product groups are Terumo Medical Corporation, Maquet Medical Systems, Medtronic plc, Haemonetics Corporation, Spectrum Medical Limited, and NeuroPace, Inc., although not all competitors are present in all product lines.” 10-K for 2025

Read from Haemonetics’s annual reports (10-K for 2026, 10-K for 2025, 10-K for 2024) and the financial data it files with the SEC, as of 2026-05-20. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.